FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Vanda Pushes Back on Hetlioz sNDA Hearing Denial

[ Price : $8.95]

A sharply-worded Vanda response to FDA says commissioner Robert Califf should reject a CDER proposed order and either approve Vand...

Priority Review for Serviers Tibsovo sNDA

[ Price : $8.95]

FDA says it will give priority review to a Servier sNDA seeking a new indication for Tibsovo to treat some adult myelodysplastic s...

Abortion Drug Can Remain on Market: Appeals Court

[ Price : $8.95]

The Fifth Circuit Court of Appeals rules that the abortion drug mifepristone can remain on the market while litigation continues.

FDAs Lighter Enforcement May be Ending: Attorney

[ Price : $8.95]

Attorney Douglas Farquhar says an FDA trend toward more enforcement discretion for drug company inspections with official action i...

New FDA PathologAI Initiative

[ Price : $8.95]

The FDA National Center for Toxicological Research says initial results from its new PathologAI initiative in preclinical animal s...

Panel to Discuss Neuroblastoma NDA

[ Price : $8.95]

Federal Register notice: FDA announces a 10/4 Oncologic Drugs Advisory Committee meeting to review a World Meds NDA eflornithine t...

Final Guide on Informed Consent

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Informed Consent: Guidance for Institutional Review Boards,...

Comments Reopened on Medicated Articles Guide

[ Price : $8.95]

Federal Register notice: FDA reopens the comment period for a 6/8 draft guidance on demonstrating bioequivalence for Type A medica...

Deficiencies in CM and RTRT-D NDA Submissions

[ Price : $8.95]

Three CDER researchers share best practices to reduce deficiencies in regulatory submissions involving real-time release testing f...

Multiple Denison Pharmaceuticals Violations

[ Price : $8.95]

FDA warns Lincoln, RI-based Denison Pharmaceuticals about CGMP violations and manufacturing unapproved new drugs.